Cargando…

Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis

OBJECTIVE: To identify circulating microRNAs (miRNAs) linked to disease stage and disability in multiple sclerosis (MS). METHODS: Sera from 296 participants including patients with MS, other neurologic diseases (Alzheimer disease and amyotrophic lateral sclerosis), and inflammatory diseases (rheumat...

Descripción completa

Detalles Bibliográficos
Autores principales: Regev, Keren, Paul, Anu, Healy, Brian, von Glenn, Felipe, Diaz-Cruz, Camilo, Gholipour, Taha, Mazzola, Maria Antonietta, Raheja, Radhika, Nejad, Parham, Glanz, Bonnie I., Kivisakk, Pia, Chitnis, Tanuja, Weiner, Howard L., Gandhi, Roopali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4996540/
https://www.ncbi.nlm.nih.gov/pubmed/27606352
http://dx.doi.org/10.1212/NXI.0000000000000267
_version_ 1782449622192488448
author Regev, Keren
Paul, Anu
Healy, Brian
von Glenn, Felipe
Diaz-Cruz, Camilo
Gholipour, Taha
Mazzola, Maria Antonietta
Raheja, Radhika
Nejad, Parham
Glanz, Bonnie I.
Kivisakk, Pia
Chitnis, Tanuja
Weiner, Howard L.
Gandhi, Roopali
author_facet Regev, Keren
Paul, Anu
Healy, Brian
von Glenn, Felipe
Diaz-Cruz, Camilo
Gholipour, Taha
Mazzola, Maria Antonietta
Raheja, Radhika
Nejad, Parham
Glanz, Bonnie I.
Kivisakk, Pia
Chitnis, Tanuja
Weiner, Howard L.
Gandhi, Roopali
author_sort Regev, Keren
collection PubMed
description OBJECTIVE: To identify circulating microRNAs (miRNAs) linked to disease stage and disability in multiple sclerosis (MS). METHODS: Sera from 296 participants including patients with MS, other neurologic diseases (Alzheimer disease and amyotrophic lateral sclerosis), and inflammatory diseases (rheumatoid arthritis and asthma) and healthy controls (HCs) were tested. miRNA profiles were determined using LNA (locked nucleic acid)-based quantitative PCR. Patients with MS were categorized according to disease stage and disability. In the discovery phase, 652 miRNAs were measured in sera from 26 patients with MS and 20 HCs. Following this, significant miRNAs (p < 0.05) from the discovery set were validated using quantitative PCR in 58 patients with MS, 30 HCs, and in 74 samples from other disease controls (Alzheimer disease, amyotrophic lateral sclerosis, asthma, and rheumatoid arthritis). RESULTS: We validated 7 miRNAs that differentiate patients with MS from HCs (p < 0.05 in both the discovery and validation phase); miR-320a upregulation was the most significantly changing serum miRNA in patients with MS. We also identified 2 miRNAs linked to disease progression, with miR-27a-3p being the most significant. Ten miRNAs correlated with the Expanded Disability Status Scale of which miR.199a.5p had the strongest correlation with disability. Of the 15 unique miRNAs we identified in the different group comparisons, 12 have previously been reported to be associated with MS but not in serum. CONCLUSIONS: Our findings identify circulating serum miRNAs as potential biomarkers to diagnose and monitor disease status in MS. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that circulating serum miRNAs can be used as biomarker for MS.
format Online
Article
Text
id pubmed-4996540
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-49965402016-09-07 Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis Regev, Keren Paul, Anu Healy, Brian von Glenn, Felipe Diaz-Cruz, Camilo Gholipour, Taha Mazzola, Maria Antonietta Raheja, Radhika Nejad, Parham Glanz, Bonnie I. Kivisakk, Pia Chitnis, Tanuja Weiner, Howard L. Gandhi, Roopali Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: To identify circulating microRNAs (miRNAs) linked to disease stage and disability in multiple sclerosis (MS). METHODS: Sera from 296 participants including patients with MS, other neurologic diseases (Alzheimer disease and amyotrophic lateral sclerosis), and inflammatory diseases (rheumatoid arthritis and asthma) and healthy controls (HCs) were tested. miRNA profiles were determined using LNA (locked nucleic acid)-based quantitative PCR. Patients with MS were categorized according to disease stage and disability. In the discovery phase, 652 miRNAs were measured in sera from 26 patients with MS and 20 HCs. Following this, significant miRNAs (p < 0.05) from the discovery set were validated using quantitative PCR in 58 patients with MS, 30 HCs, and in 74 samples from other disease controls (Alzheimer disease, amyotrophic lateral sclerosis, asthma, and rheumatoid arthritis). RESULTS: We validated 7 miRNAs that differentiate patients with MS from HCs (p < 0.05 in both the discovery and validation phase); miR-320a upregulation was the most significantly changing serum miRNA in patients with MS. We also identified 2 miRNAs linked to disease progression, with miR-27a-3p being the most significant. Ten miRNAs correlated with the Expanded Disability Status Scale of which miR.199a.5p had the strongest correlation with disability. Of the 15 unique miRNAs we identified in the different group comparisons, 12 have previously been reported to be associated with MS but not in serum. CONCLUSIONS: Our findings identify circulating serum miRNAs as potential biomarkers to diagnose and monitor disease status in MS. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that circulating serum miRNAs can be used as biomarker for MS. Lippincott Williams & Wilkins 2016-08-23 /pmc/articles/PMC4996540/ /pubmed/27606352 http://dx.doi.org/10.1212/NXI.0000000000000267 Text en © 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Article
Regev, Keren
Paul, Anu
Healy, Brian
von Glenn, Felipe
Diaz-Cruz, Camilo
Gholipour, Taha
Mazzola, Maria Antonietta
Raheja, Radhika
Nejad, Parham
Glanz, Bonnie I.
Kivisakk, Pia
Chitnis, Tanuja
Weiner, Howard L.
Gandhi, Roopali
Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
title Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
title_full Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
title_fullStr Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
title_full_unstemmed Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
title_short Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
title_sort comprehensive evaluation of serum micrornas as biomarkers in multiple sclerosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4996540/
https://www.ncbi.nlm.nih.gov/pubmed/27606352
http://dx.doi.org/10.1212/NXI.0000000000000267
work_keys_str_mv AT regevkeren comprehensiveevaluationofserummicrornasasbiomarkersinmultiplesclerosis
AT paulanu comprehensiveevaluationofserummicrornasasbiomarkersinmultiplesclerosis
AT healybrian comprehensiveevaluationofserummicrornasasbiomarkersinmultiplesclerosis
AT vonglennfelipe comprehensiveevaluationofserummicrornasasbiomarkersinmultiplesclerosis
AT diazcruzcamilo comprehensiveevaluationofserummicrornasasbiomarkersinmultiplesclerosis
AT gholipourtaha comprehensiveevaluationofserummicrornasasbiomarkersinmultiplesclerosis
AT mazzolamariaantonietta comprehensiveevaluationofserummicrornasasbiomarkersinmultiplesclerosis
AT rahejaradhika comprehensiveevaluationofserummicrornasasbiomarkersinmultiplesclerosis
AT nejadparham comprehensiveevaluationofserummicrornasasbiomarkersinmultiplesclerosis
AT glanzbonniei comprehensiveevaluationofserummicrornasasbiomarkersinmultiplesclerosis
AT kivisakkpia comprehensiveevaluationofserummicrornasasbiomarkersinmultiplesclerosis
AT chitnistanuja comprehensiveevaluationofserummicrornasasbiomarkersinmultiplesclerosis
AT weinerhowardl comprehensiveevaluationofserummicrornasasbiomarkersinmultiplesclerosis
AT gandhiroopali comprehensiveevaluationofserummicrornasasbiomarkersinmultiplesclerosis